The Venture Codex

Led · Seed · Jun 2026

TRIMTECH Therapeutics was founded on academic research into the E3-ligase TRIM21 and has developed two proprietary targeted protein degradation platforms, TRIMTAC and TRIMGLUE. The company focuses on small-molecule degraders designed to selectively remove toxic protein aggregates and oligomers while sparing functional monomeric protein. TRIMTECH is advancing CNS-penetrant degrader candidates aimed at neurodegenerative diseases with large patient populations. Its current financial position includes a seed financing round totaling $47M following a $14M extension led by JJDC and BGF. The new capital is earmarked to progress its platforms and expand the company's portfolio, and JJDC and BGF will each take board seats as non-executive directors. TRIMTECH is based in Cambridge, England.

Participated · Series A · Jun 2026

FesariusTherapeutics is a commercial-stage medical technology company headquartered in New York whose flagship product, DermiSphere™, is the first hydrogel Dermal Regeneration Template (hDRT) cleared by the FDA (510(k) clearance in January 2025). DermiSphere™ features a patented dual-density collagen microarchitecture intended to facilitate cellular integration and vascularization to support wound healing. The device is commercially active across multiple U.S. hospital systems and the company reports growing clinical momentum. Fesarius plans to pursue Breakthrough Device Designation, expanded reimbursement pathways, and a pivotal clinical trial supporting a OneStep procedure and future label expansion. The company will use proceeds from its $20 million Series A to accelerate commercial infrastructure and expand its national direct sales coverage. The financing included strategic and institutional investors, signaling validation from both corporate and specialty-society backers.

Participated · Series C · Jun 2026

CereVasc is a clinical-stage medical device company based in Massachusetts developing the eShunt System, an investigational, patented endovascularly implantable cerebrospinal fluid shunt and delivery components. The eShunt employs a percutaneous transvenous-transdural approach intended to enable a minimally invasive treatment for communicating hydrocephalus. The company is currently conducting the STRIDE pivotal trial, a prospective, multi-center, randomized, controlled study comparing the eShunt System to the standard ventriculo-peritoneal (VP) shunt to evaluate safety and effectiveness. Data from STRIDE are intended to support a future FDA Premarket Approval (PMA) submission. CereVasc describes the eShunt as investigational and not yet approved for commercial sale. The company plans to use recent Series C proceeds to complete the pivotal trial, advance regulatory work, scale operations, and prepare for U.S. commercialization.

Participated · Equity · Mar 2026

Mestag Therapeutics develops therapies by leveraging fibroblast immunology to treat cancer and inflammatory diseases. Its pipeline includes MST-0312, a FAP-targeted LTBR agonist bispecific antibody designed to exploit tertiary lymphoid structures in solid tumors, and M402, an agonist antibody targeting a stromal inhibitory receptor for inflammatory disease, alongside earlier discovery-stage programs. The company also uses its RAFT Platform to identify novel fibroblast-immune targets and has entered collaborations with MSD in 2024 and a 2021 agreement with Janssen to discover and license targets. Mestag recently raised $40M in financing to fund the Phase 1 STARLYS clinical study, expected to begin in mid-2026. Leadership includes CEO Susan Hill, with Lindsey Rolfe appointed Chief Medical Officer and Pascal Merchiers appointed Chief Development Officer.

Led · Series B · Jan 2026

EpiBiologics is a San Mateo–based biotechnology company pioneering the degradation of disease-driving extracellular membrane and soluble proteins via its proprietary EpiTAC bispecific antibody platform. The company’s lead candidate, EPI-326, is designed to degrade all oncogenic forms of EGFR in a tumor-selective manner, aiming to overcome safety and resistance limitations of current EGFR therapies. Preclinical data show strong, durable efficacy with favorable safety and pharmacokinetic profiles, supporting both monotherapy and combination use across multiple cancer types. EpiBiologics plans to commence a first-in-human trial of EPI-326 in early 2026 for non-small cell lung cancer and head and neck squamous cell carcinoma. Proceeds from its recent financing will also expand a broader pipeline in oncology and immunology while bolstering internal capabilities. The company recently strengthened its leadership team by hiring Eric Humke, M.D., Ph.D., as Chief Medical Officer and Aaron Mishel as Chief Financial Officer, and added several industry leaders to its Board.